Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $202.9 million.

  • Puma Biotechnology's Liabilities and Shareholders Equity fell 809.12% to $202.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.3 million, marking a year-over-year decrease of 725.05%. This contributed to the annual value of $213.3 million for FY2024, which is 745.9% down from last year.
  • Latest data reveals that Puma Biotechnology reported Liabilities and Shareholders Equity of $202.9 million as of Q3 2025, which was down 809.12% from $194.9 million recorded in Q2 2025.
  • Puma Biotechnology's Liabilities and Shareholders Equity's 5-year high stood at $260.0 million during Q2 2021, with a 5-year trough of $193.7 million in Q2 2022.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $205.0 million (2024), whereas its average is $213.9 million.
  • Per our database at Business Quant, Puma Biotechnology's Liabilities and Shareholders Equity skyrocketed by 1468.99% in 2021 and then tumbled by 2551.83% in 2022.
  • Puma Biotechnology's Liabilities and Shareholders Equity (Quarter) stood at $226.6 million in 2021, then decreased by 2.0% to $222.1 million in 2022, then increased by 3.81% to $230.5 million in 2023, then fell by 7.46% to $213.3 million in 2024, then fell by 4.91% to $202.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $202.9 million in Q3 2025, compared to $194.9 million in Q2 2025 and $196.2 million in Q1 2025.